Date:7/1/2008

rs, including, but not limited to: the effect of government regulation, including when and if we receive approval for marketing products in the United States; the impact of international currency fluctuations on our cash flows and operating results; the impact of technological innovation and competition; acceptance of our products by physicians and patients, our historical reliance on a single product for most of our current sales; our ability to commercialize our recently licensed product lines; our intellectual property and the ability to prevent competitors from infringing our rights; the ability to receive third party reimbursement for our products; the results of clinical trials; our continued losses and the possible need to raise additional capital in the future; our ability to manage our international operations; our ability to hire and retain key technical and sales personnel; our dependence on key suppliers; future changes in applicable accounting rules; and volatility in our stock price. We cannot assure you that inclusion in the Russell Microcap Index will broaden our investor exposure, or otherwise benefit us or our stock. We also cannot assure continued inclusion in this Index. We recommend that you read this press release in conjunction with our Annual Report on Form 10-K for the fiscal year ended March 31, 2008 on file with the SEC. Uroplasty undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Dahlia Bailey (Investors)

415.896.6820

'/>"/>

SOURCE Uroplasty, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty to Host Second Quarter Conference Call on November 1
3. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
4. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
5. Uroplasty Expands Marketing Program for Urology Practices
6. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
7. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
8. Uroplasty Plans to Double Sales Force During Fiscal 2009
9. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
10. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
11. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008